Düsseldorf, Germany-based medical technology company CUREosity announced on Monday that it has secured €3.8 million in a growth funding round from existing and new investors.
The growth funding round was joined by existing investors TechVision Fund (TVF) and Belgian family office Nomainvest, along with other new co-investors.
TVF, which specializes in investing in medical technology companies, has backed CUREosity since 2021.
The growth funding round was also supported by law firms ADVANT Beiten and Forvis Mazars.
This latest funding round will enable the German company to further advance its innovative solutions and expand its market presence.
Caesar van Heyningen, CEO of CUREosity, said: “This funding strengthens our current successful trajectory of market expansion and high-quality updates to our treatment software. We plan to integrate future technological possibilities into our current product roadmap and invest heavily in our commercial expansion. This funding round ensures our financial independence and sustainable business operations, which is a privilege, especially in a challenging market environment.”
The Birth of CUREosity
CUREO is based on the personal experiences of its founders Thomas Saur, Stefan Arand and Marco Faulhammer.
Following a car accident in 2000, Thomas Saul’s young son was left paralyzed from the waist down. Despite a search for the best care and rehabilitation, existing methods were not producing the desired results.
CUREosity co-founders Stefan Arand and Marco Faulhammer experienced similar fates and challenges, leading them to decide to develop a new form of therapy that combines their own therapeutic experience and learnings with current technology and neuroscience discoveries.
The founders have deep technical know-how through many years of experience in 3D visualization and the creation of application concepts in this field within the IT and scientific sectors.
A combination of technical skills, 3D visualization expertise, virtual reality experience, and personal motivation derived from medical suffering led to the founding of CUREosity and the birth of the idea for CUREO.
CUREosity: Gamified Virtual Reality Therapy
Led by Caesar van Heyningen, CUREosity is known for its virtual reality therapy system called CUREO for clinics and medical offices.
According to the company, the benefits of CUREO include successful evidence-based treatment, sustained reduction in personnel burden, increased patient motivation, broad application and simple, intuitive usability.
The 50 trainings across seven modules are available in physiotherapy, occupational therapy and neuropsychology.
The software is currently used in 24 countries around the world.
Investor
TechVision Fund (TVF) is an early-stage venture capital firm focused on investing in technology companies with the potential to transform major industries.
The firm’s strategy revolves around early engagement, primarily targeting seed-stage investments with occasional early Series A investments.
The company’s focus areas span SaaS/Software, IoT, Digital Solutions, MedTech, Biotech, New Materials and Greentech/Cleantech.
Björn Lang, Partner at TVF, said: “CUREOSITY solves the problem of a shortage of skilled workers in the field of therapy. Especially due to demographic changes, smart solutions like CUREOSITY are of great importance to society. We look forward to being part of the solution and succeeding in the future.”
